CN1331462C - Self microemulsion of total dragon's blood flavone - Google Patents
Self microemulsion of total dragon's blood flavone Download PDFInfo
- Publication number
- CN1331462C CN1331462C CNB200410009183XA CN200410009183A CN1331462C CN 1331462 C CN1331462 C CN 1331462C CN B200410009183X A CNB200410009183X A CN B200410009183XA CN 200410009183 A CN200410009183 A CN 200410009183A CN 1331462 C CN1331462 C CN 1331462C
- Authority
- CN
- China
- Prior art keywords
- liquid
- lourerin
- dosage form
- self
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to self-microemulsifying liquid of resina draconis total flavonoid, a capsule thereof and a preparation method thereof. The self-microemulsifying liquid is a uniform and transparent solution prepared from the components of resina draconis total flavonoid and one of auxiliary materials of solvent, dispersing agent, emulsifying agent and galactopoietic or some of the auxiliary materials. For example, the self-microemulsifying liquid can automatically form a microemulsion bead whose granularity is below 5 microns under gastric motor after the self-microemulsifying liquid is prepared into a capsule and the capsule is orally taken, thereby enhancing the bioavailability and the therapeutic effect of the self-microemulsifying liquid. The self-microemulsifying liquid has the advantages of low cost, simple process, high stability and beautiful appearance; besides, the self-microemulsifying liquid is easy to realize industrialization, and has excellent therapeutic effects on hyperlipemia, coronary heart diseases, diabetes and other diseases.
Description
Technical field
The present invention relates to Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid, particularly, capsule of the Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid that the present invention relates to include and preparation method thereof.
Background technology
Sanguis Draxonis (Dragon ' s Blood), have another name called Sanguis Draxonis, be mainly derived from the resin of Palmae Daemonorops (Dae-monorops) and Liliaceae dracaena (Dracaena) 10 various plants, be traditional rare Chinese medicine, beginning is stated from Tang Materia Medica, in China's medicinal history that has more than 1500 year among the people.Have detumescence, antiinflammatory, pain relieving, stop blooding, invigorate blood circulation, effect such as removing the necrotic tissue and promoting granulation.Compendium of Material Medica claims that it is the panacea of invigorating blood circulation.Be the traditional Chinese medical science promoting blood circulation to remove blood stasis and hemorrhage commonly used.According to textual criticism, the used Sanguis Draxonis of Song Yiqian is based on the resin of Liliaceae dracaena plant woody part, bright, clear since used Sanguis Draxonis then based on the secretions of Palmae Daemonorops plant.Its source relies on import for a long time.For a change Sanguis Draxonis relies on the situation of import over the years, just carry out the prospecting in Sanguis Draxonis medicine source from the beginning of the seventies in Yunnan and Guangxi emphasis, the famous botanist Cai Xitao professor of China at first finds dracaena cambodiana Pierre in the southern regions of the Yunnan Province, thinks that through preliminary study it makes the Sanguis Draxonis Application Prospect." Yunnan Province's drug standard " (1974) have recorded this Sanguis Draxonis, and plant-origin is dracaena cambodiana Pierre Dracaena canbodiana Pierreex Gagnep.." Chinese Plants will " the 14 volume revision dracaena cambodiana Pierre formal name used at school determine that its former plant is a Dracaena cochinchinensis, so the Yunnan Sanguis Draxonis is consistent with the plant-origin of Guangxi Sanguis Draxonis.Domestic Dragon Blood proves that through drug effect, toxicity and clinical research in more than 20 years its every index meets or exceeds present import Sanguis Draxonis, can be used as Sanguis Draxonis fully and uses.
Domestic Dragon Blood (Sanguis Draxonis) derives from dracaena cambodiana Pierre Dracaena canbodianaPierreex Gagnep..Domestic Dragon Blood mainly contains flavonoid, volatile oil, cardiotonic glycoside, anthraquinone, tannin and other phenoloid.
Modern medicine study confirms that Sanguis Draxonis has the body of improvement microcirculation, improves effects such as body's immunity.It can make the blood that is in hypercoagulability circulate again, plays function of promoting blood circulation to disperse blood clots; The blood that is in hypocoagulability is solidified at blood vessel cut place and make stopped bleeding, play anastaltic effect, have dual regulation aspect the Chinese traditional treatment blood disorder.Be mainly used in coronary heart disease, hyperlipidemia, cerebral infarction, peptic ulcer, upper respiratory tract hemorrhage, gastritis, colitis, type ii diabetes, hyperthyroidism etc. clinically.
Sanguis Draxonis is widely used in clinical multiple treatment of diseases as the panacea of invigorating blood circulation, and is evident in efficacy reliable, has no side effect, and is national essential drugs.But have only Sanguis Draxonis powder or Sanguis Draxonis powder capsule at present for clinical use, taking dose is big, thereby has limited its range of application.Water insoluble owing to Sanguis Draxonis simultaneously, absorption difference, bioavailability is not high, and its good drug effect is not fully exerted.
At the shortcoming of the former medicated powder of above-mentioned Sanguis Draxonis, prior art has proposed multiple improving one's methods.
For example CN1265321A discloses a kind of Resina Draconis preparation as one and preparation method thereof, described preparation is mixed and made into the Sanguis Draxonis solid dispersion by the former medicated powder of Sanguis Draxonis and solid dispersion such as cyclodextrin, cellulose, Polyethylene Glycol, poloxamer or Myrij etc., further makes capsule, tablet etc. according to a conventional method.
CN1457835A discloses a kind of Sanguis Draxonis drop pill and preparation method thereof, and described drop pill is added in the substrate of melting such as Polyethylene Glycol, poloxamer, the stearic acid etc. by fine powder of dragons blood and makes.
CN1483432A discloses a kind of Sanguis Draxonis inclusion, and it is made up of fine powder of dragons blood and beta-schardinger dextrin-.
Because the crude drug that uses is the former medicated powder of Sanguis Draxonis, above-mentioned patent application still can not be satisfactory aspect dissolubility, absorbability and the bioavailability of Sanguis Draxonis composition and drug effect performance.
Modern study proves that the contained flavone compound of Sanguis Draxonis is the effective ingredient of Sanguis Draxonis blood circulation promoting and blood stasis dispelling.The present inventor discovers by intensive, with the Sanguis Draxonis flavoniod effective ingredient, adopt the self-emulsifying micro-emulsion technology, be made into liquid capsule, can obviously improve the dissolubility of Sanguis Draxonis flavoniod, significantly improve its bioavailability, give full play to it as invigorating blood circulation the effect of panacea, so and finished the present invention.
Self-emulsifying drug delivery system (Self-emulsifying drug delivery system, SEDDS) be under the no water situation, by active constituents of medicine and emulsifying agent and/or help Emulsion and thermodynamically stable uniform solution that optional solvent and/or dispersant form, generally be sub-packed in soft capsule or the transparent hard capsule (liquid capsule); Oral back is at the gastric juice aqueous phase, spontaneous formation granularity is the Emulsion about 5 microns owing to the existence of gastric peristalsis and emulsifying agent (being often referred to about 37 ℃) under the physiological environment temperature, thereby be distributed in fast in the whole gastrointestinal tract, reduced the stimulation that medicine causes with direct contact of gastrointestinal wall; The distribution of medicine between oil/water is biphase relies on the huge specific surface area of microemulsion and the stripping that improved water-insoluble drug greatly, improves bioavailability of medicament, can also avoid the hydrolysis of water unstable medicine and medicine to the gastrointestinal pessimal stimulation simultaneously.
Lipid-lowering medicine, antithrombotic are the medicines of global sales maximum, only fall the ester medicine and promptly reach 30,000,000,000 dollars the market share.Along with the world population senescence, its market share will enlarge.Simultaneously, currently used medicine mostly is insoluble chemical compound, and bioavailability is low, and the medication period limit for length, and liver and gall are all had side effect, like this as determined curative effect, and safety, the little natural Resina Draconis preparation as one of side effect will have immeasurable market potential.
Summary of the invention
The purpose of this invention is to provide a kind of Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid, it is characterized in that: it contains Sanguis Draxonis flavoniod and emulsifying agent and/or helps Emulsion and optional solvent and/or dispersant.Generally speaking, contain the emulsifying agent of 5-90% Sanguis Draxonis flavoniod, 10-95% by weight and/or help Emulsion and 0-80% solvent and/or dispersant by weight from littleization fluid component; Preferably, contain the emulsifying agent of 5-80% Sanguis Draxonis flavoniod, 10-80% by weight and/or help Emulsion and 5-80% solvent and/or dispersant by weight; More preferably, contain the emulsifying agent of 5-50% Sanguis Draxonis flavoniod, 10-50% by weight and/or help Emulsion and 5-50% solvent and/or dispersant by weight.
Another object of the present invention provides a kind of capsule that includes Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid, it is characterized in that: containing Sanguis Draxonis flavoniod and emulsifying agent and/or helping Emulsion and optional solvent and/or dispersant from littleization fluid component in the capsule.Generally speaking, contain the emulsifying agent of 5-90% Sanguis Draxonis flavoniod, 10-95% by weight and/or help Emulsion and 0-80% solvent and/or dispersant by weight from littleization fluid component; Preferably, contain the emulsifying agent of 5-80% Sanguis Draxonis flavoniod, 10-80% by weight and/or help Emulsion and 5-80% solvent and/or dispersant by weight; More preferably, contain the emulsifying agent of 5-50% Sanguis Draxonis flavoniod, 10-50% by weight and/or help Emulsion and 5-50% solvent and/or dispersant by weight.
Another object of the present invention is that the capsular preparation method that includes Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid also is provided, it is characterized in that: Sanguis Draxonis flavoniod is added emulsifying agent and/or helps Emulsion, when selecting solvent and/or dispersant for use, can earlier Sanguis Draxonis flavoniod be dissolved in solvent and/or dispersant, after the mixing, stir, again by fill, seal and make the capsule that content is a transparent and homogeneous liquid, also claim liquid capsule.According to the difference of selecting cyst material for use, described liquid capsule can also be divided into soft capsule or hard capsule.
Can be used for emulsifying agent of the present invention and/or help Emulsion to include but not limited to: polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides, polyglycereol dioleate, poloxamer, Brij (Brij), Myrij (Mjri) and sucrose ester etc.; Preferably, polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides and polyglycereol dioleate.
Can be used for solvent of the present invention and/or dispersant is to be the polyalcohols of liquid under the room temperature, can exemplify for example Liquid Macrogol-600, propylene glycol or glycerol etc.
The preferred embodiment of the invention is to select for use solvent and/or dispersant as one of self emulsifying component.Under the situation of not selecting solvent and/or dispersant for use, emulsifying agent and/or to help Emulsion to select for use under the room temperature be the kind of liquid; The emulsifying agent of perhaps selecting for use and/or help that to have at least a kind of in the Emulsion composition be liquid, mixing the back is the kind of liquid.
In the embodiment preferred, the invention provides a kind of capsule that includes Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid, it is characterized in that: containing the emulsifying agent of 5-50% Sanguis Draxonis flavoniod, 10-50% by weight and/or helping Emulsion and 5-50% solvent and/or dispersant by weight in the capsule from littleization fluid component, wherein, solvent and/or dispersant are the liquid polyhydric alcohols, for example are at least a in Liquid Macrogol-600, propylene glycol or the glycerol etc.
Sanguis Draxonis flavoniod of the present invention is known, perhaps can adopt conventional or known method preparation, referring to for example CN1482124A or CN1481788A.Sanguis Draxonis flavoniod can also adopt conventional mode refining, to improve content of effective in the Sanguis Draxonis flavoniod.Preferably Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, and in lourerin A and/or lourerin B, general flavone content is more than 30%, more preferably more than 50%.
Preparation of the present invention can also contain other medicinal adjuvant for example antioxidant such as ascorbic acid, tea polyphenols, tocopherols etc.
Sanguis Draxonis flavoniod self emulsifying liquid of the present invention can adopt usual manner to make various pharmaceutical dosage forms.For example, can be processed into dosage forms such as tablet, capsule, solid dispersion sheet, fast-release tablet, drop pill by adding suitable pharmaceutic adjuvant.Preferred dosage form is that capsule comprises soft capsule and hard capsule.In capsule of the present invention, the capsule-wall material of employing does not have special qualification, can be the material that routine is used to prepare pharmaceutical soft capsule or hard capsule.
After Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid of the present invention is oral, under physiological environment temperature and gentle agitation, can spontaneous emulsification formation granularity be lower than 5 microns Emulsion.
Sanguis Draxonis flavoniod make the microemulsion style as make include capsule after, make it have the advantage of self emulsifying medicinal liquid, for example, oral back is at the gastric juice aqueous phase, spontaneous formation granularity is the Emulsion about 5 microns owing to the existence of gastric peristalsis and emulsifying agent (being often referred to about 37 ℃) under the physiological environment temperature, thereby be distributed in fast in the whole gastrointestinal tract, reduced the stimulation that medicine causes with direct contact of gastrointestinal wall; Distribution between oil/water is biphase relies on the huge specific surface area of microemulsion and the stripping that improved the water-insoluble drug composition greatly, improves bioavailability of medicament, can also avoid the hydrolysis of water unstable medicine and medicine to the gastrointestinal pessimal stimulation simultaneously.Thereby overcome Sanguis Draxonis class medicine (comprising for example Sanguis Draxonis flavone of its extract) owing to water insoluble, absorption difference, bioavailability is not high, the defective that makes its good drug effect be difficult to give full play to.
Sanguis Draxonis flavoniod can improve its stability and bioavailability after making self-emulsifying microemulsion liquid, gives full play to its therapeutical effect as " panacea of invigorating blood circulation ".More be applicable to disease treatments such as coronary heart disease, hyperlipidemia, cerebral infarction, peptic ulcer, upper respiratory tract hemorrhage, gastritis, colitis, type ii diabetes, hyperthyroidism.
The specific embodiment
Embodiment 1
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 5
Liquid Macrogol 20
Polyoxyethylene Sorbitan Monooleate 5
Preparation method: taking polyethylene glycol 300, under 60-70 ℃, add Polyoxyethylene Sorbitan Monooleate, Sanguis Draxonis flavoniod, stir, insulation down fill in transparent hard capsule, seal promptly.
Embodiment 2
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 5
Polyoxyethylene decanoyl/octanoyl glycerides 20
Sodium lauryl sulphate 5
Preparation method: under 60-70 ℃, add polyoxyethylene decanoyl/octanoyl glycerides, sodium lauryl sulphate and Sanguis Draxonis flavoniod, stir, insulation down fill in transparent hard capsule, seal promptly.
Embodiment 3
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 10
Propylene glycol 20
Soybean lecithin 3
Polyoxyethylene Sorbitan Monooleate 12
Preparation method: be similar to embodiment 1.
Embodiment 4
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 10
PEG400 20
Soybean lecithin 3
Polyoxyethylene Sorbitan Monooleate 12
Preparation method: be similar to embodiment 1.
Embodiment 5
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 5
Propylene glycol 20
Lecithin 5
Polyoxyethylene Sorbitan Monooleate 10
Preparation method: be similar to embodiment 1.
Embodiment 6
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 10
Glycerol 20
Mono stearate glyceryl ester 5
Poloxamer 5
Preparation method: be similar to embodiment 1.
Embodiment 7
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 5
Liquid Macrogol 10
Soybean lecithin 5
Polysorbate-60 10
Preparation method: be similar to embodiment 1.
Embodiment 8
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 15
Propylene glycol 20
Polyglycereol dioleate 15
Preparation method: be similar to embodiment 1.
Embodiment 9
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 15
Propylene glycol 20
Lecithin 5
Myrij 10
Preparation method: be similar to embodiment 1.
Embodiment 10
Form from littleization liquid: (g)
Sanguis Draxonis flavoniod 5
Glycerol 20
Brij 15
Preparation method: be similar to embodiment 1.
Experimental example 1: Sanguis Draxonis flavoniod is to hemorheological influence
Experiment grouping and dosage design
Laboratory animal is divided into 6 groups at random:
(1) solvent control group: 10 of laboratory animals.Gavage 0.25%CMC 10ml/kg body weight every day, continuous seven days.
(2) blood stasis model group: 10 of laboratory animals.Gavage 0.25%CMC every day, 10ml/kg body weight, continuous seven days.
(3) positive drug FUFANG DANSHEN PIAN group: 10 of laboratory animals.Gavage compound Salviae Miltiorrhizae 1.0g/kg body weight every day, continuous seven days.
(4) the heavy dose of group of Sanguis Draxonis: 10 of laboratory animals.Gavage Sanguis Draxonis flavoniod 100mg/kg body weight every day, continuous seven days.
(5) dosage group in the Sanguis Draxonis: 10 of laboratory animals.Gavage Sanguis Draxonis flavoniod 50mg/kg body weight every day, continuous seven days.
(6) Sanguis Draxonis small dose group: 10 of laboratory animals.Gavage Sanguis Draxonis flavoniod 25mg/kg body weight every day, continuous seven days.
Experimental procedure: in the 7th day except that the blank group, each organizes the equal subcutaneous injection adrenalin hydrochloride of rat (Adr) 0.08ml/100g, totally twice, two minor tick is 4 hours, and (front and back each at interval 2 hours) were immersed rat in the 1 degree left and right sides frozen water 5 minutes between double injection Adr.Stop eating inferior abdominal aortic blood survey in morning hemorheology index (the full-automatic hemorheology measuring and analysing meter of MDK3200) after the disposal.The results are shown in Table 1:
Table 1 Sanguis Draxonis flavoniod is to the influence of hemorheology of rat (X ± SD)
| Group | Dosage (mg/kg) | Whole blood contrast viscosity | The plasma viscosity ratio | Packed cell volume (%) | Erythrocyte electrophoretic time | |
| Height is cut | Low cutting | |||||
| Solvent control group blood stasis model group Sanguis Draxonis flavoniod Sanguis Draxonis flavoniod Sanguis Draxonis flavoniod FUFANG DANSHEN PIAN | 100 50 25 1000 | 4.25±0.07 4.95±0.32## 3.85±0.20*** 4.22±0.22** 4.47±0.36 3.95±0.17*** | 5.05±0.24 7.45±0.22### 5.25±0.73*** 5.85±0.67** 7.35±0.85 5.35±0.26*** | 1.15±0.08 1.65±0.03### 1.55±0.08* 1.53±0.06* 1.75±0.07 1.45±0.07*** | 39.5±1.6 43.1±4.6 31.8±3.2*** 29.1±1.4*** 33.8±2.4** 31.0±3.8** | 28.1±3.16 36.54±4.46# 27.50±2.14** 27.45±2.41*** 35.10±3.64 28.53±2.89** |
Annotate: the experiment of this experimental example uses the Sanguis Draxonis flavoniod material to adopt the self emulsifying liquid of embodiment 1, and dosage wherein refers to the Sanguis Draxonis flavoniod amount.
Compare with the solvent control group: # represents P＜0.05, and ## represents P＜0.01, and ### represents P＜0.001; Compare with the blood stasis model group:
*Expression P＜0.05,
*Expression P＜0.01,
* *Expression P＜0.001.
The result shows: Sanguis Draxonis flavoniod 100mg/kg body weight, 50mg/kg body weight continuous irrigation stomach 7 days, all can obviously reduce the high viscous state of stasis syndrome disease rat blood, whole blood viscosity, plasma viscosity and packed cell volume obviously reduce, shorten erythrocyte electrophoretic time, the effect of 25mg/kg group is not obvious.
Above embodiment is only for the present invention is further illustrated, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Claims (35)
1. Sanguis Draxonis flavoniod self-emulsifying microemulsion liquid is characterized in that: it is by the emulsifying agent of 5-80% Sanguis Draxonis flavoniod, 10-80% by weight and/or help Emulsion and 5-80% solvent and/or dispersant are formed by weight.
2. according to the self-emulsifying microemulsion liquid of claim 1, wherein, described from littleization fluid component by the emulsifying agent of 5-50% Sanguis Draxonis flavoniod, 10-50% by weight and/or help Emulsion and 5-50% solvent and/or dispersant are formed by weight.
3. according to the self-emulsifying microemulsion liquid of claim 1 or 2, wherein, it is the polyalcohols of liquid that described solvent and/or dispersant are selected under the room temperature.
4. according to the self-emulsifying microemulsion liquid of claim 3, wherein, described polyhydric alcohol is selected from one or more in Liquid Macrogol-600, propylene glycol, the glycerol.
5. according to the self-emulsifying microemulsion liquid of claim 1, wherein, described emulsifying agent and/or help Emulsion to be selected from polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides, polyglycereol dioleate, poloxamer, Brij, Myrij and the sucrose ester one or more.
6. according to the self-emulsifying microemulsion liquid of claim 2, wherein, described emulsifying agent and/or help Emulsion to be selected from polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides, polyglycereol dioleate, poloxamer, Brij, Myrij and the sucrose ester one or more.
7. according to the self-emulsifying microemulsion liquid of claim 4, wherein, described emulsifying agent and/or help Emulsion to be selected from polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides, polyglycereol dioleate, poloxamer, Brij, Myrij and the sucrose ester one or more.
8. according to the self-emulsifying microemulsion liquid of claim 3, wherein, described emulsifying agent and/or help Emulsion to be selected from polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides, polyglycereol dioleate, poloxamer, Brij, Myrij and the sucrose ester one or more.
9. according to the self-emulsifying microemulsion liquid of claim 5, wherein, described emulsifying agent and help Emulsion to be selected from polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides and the polyglycereol dioleate one or more.
10. according to the self-emulsifying microemulsion liquid of claim 6, wherein, described emulsifying agent and help Emulsion to be selected from polysorbate, lecithin, soybean lecithin, sodium lauryl sulphate, mono stearate glyceryl ester, polyoxyethylene decanoyl/octanoyl glycerides and the polyglycereol dioleate one or more.
11. according to the self-emulsifying microemulsion liquid of claim 1, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, in lourerin A and/or lourerin B, general flavone content is more than 30%.
12. according to the self-emulsifying microemulsion liquid of claim 2, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, in lourerin A and/or lourerin B, general flavone content is more than 30%.
13. according to the self-emulsifying microemulsion liquid of claim 4, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, in lourerin A and/or lourerin B, general flavone content is more than 30%.
14. according to the self-emulsifying microemulsion liquid of claim 6, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, in lourerin A and/or lourerin B, general flavone content is more than 30%.
15. according to the self-emulsifying microemulsion liquid of claim 7, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, in lourerin A and/or lourerin B, general flavone content is more than 30%.
16. self-emulsifying microemulsion liquid according to Claim 8, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, and in lourerin A and/or lourerin B, general flavone content is more than 30%.
17. according to the self-emulsifying microemulsion liquid of claim 3, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, in lourerin A and/or lourerin B, general flavone content is more than 30%.
18. according to the self-emulsifying microemulsion liquid of claim 5, wherein, described Sanguis Draxonis flavoniod contains lourerin A5-30%, lourerin B 5-40%, in lourerin A and/or lourerin B, general flavone content is more than 30%.
19. the pharmaceutical dosage form from littleization liquid of claim 1, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
20. the pharmaceutical dosage form from littleization liquid of claim 2, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
21. the pharmaceutical dosage form from littleization liquid of claim 4, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
22. the pharmaceutical dosage form from littleization liquid of claim 6, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
23. the pharmaceutical dosage form from littleization liquid of claim 7, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
24. the pharmaceutical dosage form from littleization liquid of claim 8, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
25. the pharmaceutical dosage form from littleization liquid of claim 10, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
26. the pharmaceutical dosage form from littleization liquid of claim 11, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
27. the pharmaceutical dosage form from littleization liquid of claim 3, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
28. the pharmaceutical dosage form from littleization liquid of claim 5, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
29. the pharmaceutical dosage form from littleization liquid of claim 9, wherein, described dosage form is tablet, capsule, solid dispersion sheet, fast-release tablet or drop pill.
30. according to the pharmaceutical dosage form of claim 12, wherein, described dosage form is a capsule.
31. according to the pharmaceutical dosage form of claim 13, wherein, described dosage form is a capsule.
32. according to the pharmaceutical dosage form of claim 14, wherein, described dosage form is a capsule.
33. according to the pharmaceutical dosage form of claim 15, wherein, described dosage form is a capsule.
34. method for preparing claim 16 pharmaceutical dosage form, it is characterized in that: Sanguis Draxonis flavoniod is added emulsifying agent and/or helps Emulsion, when selecting solvent and/or dispersant for use, can earlier Sanguis Draxonis flavoniod be dissolved in solvent and/or dispersant, after the mixing, stir, again by fill, seal and make the capsule that inclusions is a liquid.
35. method for preparing claim 17 pharmaceutical dosage form, it is characterized in that: Sanguis Draxonis flavoniod is added emulsifying agent and/or helps Emulsion, when selecting solvent and/or dispersant for use, can earlier Sanguis Draxonis flavoniod be dissolved in solvent and/or dispersant, after the mixing, stir, again by fill, seal and make the capsule that inclusions is a liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410009183XA CN1331462C (en) | 2004-06-08 | 2004-06-08 | Self microemulsion of total dragon's blood flavone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410009183XA CN1331462C (en) | 2004-06-08 | 2004-06-08 | Self microemulsion of total dragon's blood flavone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1706403A CN1706403A (en) | 2005-12-14 |
| CN1331462C true CN1331462C (en) | 2007-08-15 |
Family
ID=35580636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410009183XA Expired - Fee Related CN1331462C (en) | 2004-06-08 | 2004-06-08 | Self microemulsion of total dragon's blood flavone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1331462C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389405A (en) * | 2011-11-18 | 2012-03-28 | 中国药科大学 | Tripterine oral self-emulsification dispersible tablet and its preparation method |
| CN106109844A (en) * | 2015-05-08 | 2016-11-16 | 江苏康缘药业股份有限公司 | Sanguis Draxonis phenols extract improves the purposes in hemorheologic agent in preparation |
| CN111704536A (en) * | 2020-06-15 | 2020-09-25 | 上海大学 | Natural product Loureirin B analogue, preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1366877A (en) * | 2002-02-06 | 2002-09-04 | 中国人民解放军第二军医大学 | Chinese medicine volatile self-emulsification medicine-releasing system |
-
2004
- 2004-06-08 CN CNB200410009183XA patent/CN1331462C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1366877A (en) * | 2002-02-06 | 2002-09-04 | 中国人民解放军第二军医大学 | Chinese medicine volatile self-emulsification medicine-releasing system |
Non-Patent Citations (1)
| Title |
|---|
| 自乳化和自微乳化释药系统 沈熊，复旦学报(医学版)，第30卷第2期 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1706403A (en) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104224711B (en) | Paclitaxel submicron emulsion taking steroid compound as intermediate vector | |
| EP1878445A1 (en) | A method, formulation and use thereor with improved oral absorption of drugs or nutrients | |
| CN103083557A (en) | Traditional Chinese medicine composition with functions of reducing blood pressure and blood fat | |
| CN106619588A (en) | Self-microemulsion nutrient composition containing coenzyme Q10 and preparation method and application | |
| CN100411609C (en) | Nano-emulsion drug of triperygium wilfordii polycoride and preparation method thereof | |
| CN100412545C (en) | Method for controlling quality of compound red sage root preparation used for treating cardio-cerebral vascualr disease | |
| CN101143142A (en) | Silybin supersaturated self-emulsion composition and preparation method thereof | |
| CN104306447B (en) | A kind of pair of rattan micro emulsion gels and preparation method thereof | |
| JPH07242536A (en) | Gelatin capsule agent containing essential oil component in skin | |
| CN100477997C (en) | Hydrophobic formulation containing total notoginseng glycosides and phospholipid and preparation method thereof | |
| CN1331462C (en) | Self microemulsion of total dragon's blood flavone | |
| CN105311622B (en) | A kind of combination medicine that treating pain and its preparation, preparation method | |
| CN101933919A (en) | Application of brown cyanidin | |
| KR100588771B1 (en) | Silymarin-containing pharmaceutical composition and soft capsules containing the same | |
| CN102949415B (en) | Propolis fat emulsion preparation and preparation method thereof | |
| CN103054932A (en) | Application of albizia chinensis extract in preparation of medicament for treating gastric ulcer | |
| CN102274274B (en) | Self-microemulsifiable kudzu root flavone oral micro-pill composition and preparation method thereof | |
| CN100453072C (en) | Isatis root drops and preparation thereof | |
| CN100515427C (en) | self emulsifying soft capsule of breviscapine and its preparation | |
| CN101422454B (en) | Omega-3 polyunsaturated fatty acid tanshinone IIA sub-microemulsion and preparation method thereof | |
| CN100358496C (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN101120969A (en) | Medicine for treating diabetes and its complications and preparing method thereof | |
| CN1682884A (en) | Ginkgo leaf soft capsule and its preparing method | |
| CN101543473A (en) | Micro-emulsion composition of etoposide oral medicament, preparation method and application thereof | |
| CN101912447A (en) | Rhizoma corydalis total alkaloids self-emulsifying drug delivery system and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUILIN JIQI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: GUILIN JIQI PHARMACEUTICAL INDUSTRY CO., LTD. Effective date: 20110907 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110907 Address after: Huan Cheng Nan Qixing District, Guilin city 541004 the Guangxi Zhuang Autonomous Region Road No. 36 Building 2 water treatment plant Patentee after: Guilin Ji Qi Pharmaceutical Co., Ltd. Address before: 541004 No. 55 Yucai Road, Qixing District, Guilin, the Guangxi Zhuang Autonomous Region Patentee before: Guilin Jiqi Pharmaceutical Industry Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070815 Termination date: 20160608 |